

July 29, 2010

Mitsubishi Tanabe Pharma Corporation

Revision to First Half Year Consolidated Financial Forecasts for Fiscal Year Ending March 31, 2011

Osaka, Japan, July 29, 2010---Mitsubishi Tanabe Pharma Corporation announced today the revision to first half year consolidated financial forecasts for fiscal year ending March 31, 2011.

1. Revised first half year consolidated financial forecasts for the fiscal year ending March 31, 2011 (April 1, 2010 to September 30, 2010)

	Sales (Millions of yen)	Operating income (Millions of yen)	Ordinary income (Millions of yen)	Net income (Millions of yen)	Net income per share (Yen)
Previous forecast (A)	-	-	-	-	-
Revised forecast (B)	198,000	31,000	31,000	16,000	28.51
Difference (B-A)	-	-	-	-	-
Percentage of change %	-	-	-	-	-
(Reference) Results in the same period of the previous fiscal year	198,239	27,456	27,910	13,552	24.15

2. Reason for revision

As of May 12, 2010, when the Company announced the consolidated results forecasts for the fiscal year ending March 31, 2011, the influence of the administrative action related to Medway Injection was considered to be uncertain. Consequently, at that time the Company did not provide results forecasts for the first six months of the fiscal year ending March 31, 2011.

At this time, taking into account the consolidated results in the first three months of the fiscal year ending March 31, 2011, the Company's consolidated results forecasts for the first six months of the current fiscal year are as follows.

The influence of the administrative action related to Medway Injection remains uncertain, and as a result, at this time, there are no revisions to the consolidated results forecasts for

the current fiscal year.

(Reference) Consolidated financial forecasts for fiscal year ending March 31, 2011.

	Sales (Millions of yen)	Operating income (Millions of yen)	Ordinary income (Millions of yen)	Net income (Millions of yen)	Net income per share (Yen)
Consolidated financial forecasts for fiscal year ending March 31, 2011.	380,000	55,000	55,000	27,000	48.11

(Note) The results forecasts above are based on a number of assumptions and beliefs in light of the information available to management at this time and are subject to risks and uncertainties. Actual financial results may differ materially from these forecasts depending on a number of important factors.